FDA will meet user fee goals
Executive Summary
Shortly after Office of New Drugs Director John Jenkins granted CDER staff permission to miss PDUFA goals, Commissioner Andrew von Eschenbach reaffirmed FDA's commitment to the user fee program. "We intend to live up to the commitments that are outlined in those user fee programs. They will be difficult to adhere to because of the complexities of bringing personnel into the agency," he said at the FDLI conference March 26 (1"The Pink Sheet," March 17, 2008, p. 11). However, "we have a very detailed and month-by-month program with targets and methods of acquisition across the various centers, and ... we have approximately met about one-quarter to one-third of [the] target at this point.
You may also be interested in...
FDA Misses User Fee Goals As Resources Tighten For Application Reviews, SPAs
With the ink of the reauthorized Prescription Drug User Fee Act still drying, FDA is signaling that it may be some time before the agency will consistently meet the performance goals of its user fee program
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.